

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No. : *See*, Schedule A attached herewith

Assignee : BESINS INTERNATIONAL-USA and LABORATOIRES  
BESINS INTERNATIONAL (collectively "BESINS  
HEALTHCARE INC.")

Customer No. : 11030

**REVOCATION OF POWER OF ATTORNEY**  
**WITH NEW POWER OF ATTORNEY**  
**AND CHANGE OF CORRESPONDENCE ADDRESS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

BESINS INTERNATIONAL-USA and LABORATOIRES BESINS  
INTERNATIONAL (collectively "BESINS HEALTHCARE INC."), the assignees of 50% of the  
right, title, and interest in the applications identified in Schedule A, attached herewith, hereby  
revoke all previous powers of attorney given in the applications identified in Schedule A.

BESINS INTERNATIONAL-USA, LABORATOIRES BESINS  
INTERNATIONAL, and BESINS HEALTHCARE INC. hereby appoint the practitioners  
associated with the Customer Number 11030 as attorneys to transact all business connected with  
the applications identified in Schedule A.

Please change the correspondence address for the applications identified in  
Schedule A to the address associated with Customer Number 11030. The address associated  
with Customer Number 11030 for all future correspondence is:

Daniel J. Hulseberg  
Baker Botts L.L.P.  
30 Rockefeller Plaza  
New York, New York 10112

Pursuant to an Agreement Regarding Certain Patent Matters ("the Agreement"), effective as of August 1, 2000, between UNIMED PHARMACEUTICALS, INC. (now UNIMED PHARMACEUTICALS, LLC.), BESINS INTERNATIONAL-USA, INC., and LABORATORIES BESINS INTERNATIONAL, SAS. (collectively referred to as the "Parties"), UNIMED PHARMACEUTICALS, INC. will diligently prosecute and maintain the applications identified in Schedule A using counsel of its choice.


Additionally, pursuant to the Agreement, and a subsequent Assignment to the Agreement, the applications listed on Schedule A are and shall be jointly owned by LABORATORIES BESINS INTERNATIONAL, SAS. and UNIMED PHARMACEUTICALS, INC., with LABORATORIES BESINS INTERNATIONAL, SAS., and UNIMED PHARMACEUTICALS, INC. each owning an undivided one-half interest in the same in all countries in which patent prosecution is pursued as mutually agreed by the Parties

A Statement Under 37 C.F.R. 3.73(b) is submitted herewith. The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Dated: 10 Nov 2010

By:   
Name: Thomas W. MacAllister  
Title: Vice President  
BESINS INTERNATIONAL-USA

Dated: 17 Nov 2010

By:   
Name: Leslie Grunfeld  
Title: Managing Director  
LABORATOIRES BESINS INTERNATIONAL